Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Condition:   Hidradenitis Suppurativa Intervention:   Drug: secukinumab Sponsor:   Novartis Pharmaceuticals Not yet recruiting

Source: ClinicalTrials.gov - November 27, 2019 Category: Research Source Type: clinical trials